Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Sep 30 - Oct 5
Our team at Yorktown Health provides comprehensive chronic disease management to help coordinate all aspects of your care
A slow injection helps minimize pain and promotes proper delivery of the medication
(Kailera), a clinical-stage biopharmaceutical company focused on advancing a differentiated, late-stage portfolio of next-generation therapies for the treatment of obesity, today announced the presentation of additional data from Hengruis Phase 3 clinical trial 1 (GEMINI-1) of a once-weekly subcutaneous injection of HRS9531, a novel dual GLP-1/GIP receptor agonist, in individuals living with obesity or overweight in China (NCT06396429) at ObesityWeek 2025, the annual meeting of The Obesity Society (TOS)
without insurance you pay cash
US$ 24.98
US$ 22.91
US$ 27.30
US$ 20.75
US$ 20.22
